CT Open to Enrollment

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Germ cell tumors are formed by a type of reproductive cell called a germ cell. About 85% of children with germ cell tumors survive after treatment. Despite this good survival rate, many patients develop side effects from their treatment later in their lives (known as late effects). These late effects include a higher risk of getting another cancer or heart disease.
   

Sequential Prostate Artery Embolization and Radiation Therapy Evaluation: SPARE

The purpose of this study is to learn more about the outcomes of prostate artery embolization (PAE) and evaluate the safety of PAE prior to radiation therapy for prostate cancer.

Study participation also includes study visits, surveys, and sample collection.

A phase II/III, open-label, international, multi-center, randomized study of AAA817 versus standard of care in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu PSMA

This clinical trial is for men and women with prostate-specific membrane antigen (PSMA)-positive metastatic castrate resistant prostate cancer (mCRPC) who have previously been treated with androgen receptor pathway inhibitor (ARPI) and taxane-containing regimen, and who progressed on or after treatment with [177Lu]Lu-PSMA targeted therapy.
   
The purpose of the study is to determine if the new experimental drug AAA817 is safe and effective (can help people with prostate cancer) compared to standard treatments (SoC).
   

Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate MGL-3196 (Resmetirom) in Patients with MASH Who Have Undergone Liver Transplant for MASH Cirrhosis or Other Etiologies

This study is for men and women who have undergone a liver transplant and have been diagnosed with metabolic dysfunction-associated steatohepatitis (MASH), a liver disease associated with fat buildup and inflammation in the liver. This study will test the investigational/study drug resmetirom.
   

AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

This study is for men and women who have been diagnosed with primary biliary cholangitis (PBC), a chronic liver disease that slowly damages the bile ducts in the liver. This study will test the investigational/study drug Seladelpar.

Seladelpar has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of PBC. However, this study is being conducted to further evaluate its safety and effectiveness.

Biorepository of healthy subjects after vaccination or infection with common vaccines and community infectious diseases or from healthy control subjects

We are collecting samples so they can be made available to future research scientists who hope to study the human body’s immune response to common infectious illness such as influenza or SARS-CoV-2. This means these samples can be used for other people’s research studies. Participants are healthy adults who have a history of coronavirus and/or influenza, vaccine history or lack thereof, and absence of immunocompromise. 
   

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

This clinical trial is for adults who have been diagnosed with a cancer called Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The purpose of this study is to test if BGB-16673 and pirtobrutinib are safe and test how well BGB-16673 compares to pirtobrutinib in participants with previously treated CLL or SLL. 
   
Participants will be randomly assigned (like the flip of a coin) to receive study treatment with either BGB-16673 (Arm A of the study) or pirtobrutinib (Arm B).
   

A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors

This clinical trial is for adults who have an advanced solid tumor that has been treated with approved standard therapy and who have experienced disease progression following this prior treatment. The advanced solid tumor must be either non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), or head and neck squamous cell carcinoma (HNSCC).
   

ASPECT Study (Assessment of SIGNATERA genome PErformance across Cancer Types)

 This clinical trial is for adults who have a confirmed diagnosis of solid tumor cancer associated with a risk of recurrence or progression (meaning that the cancer could come back or worsen).